,6,7 While EGFR inhibition is effective in CRC patients with wild-type (WT) KRAS, approximately 40% of metastatic CRC cases harbor oncogenic KRAS mutations, conferring resistance to EGFR inhibitors.8 Here, KRAS is linked to colorectal carcinoma.